Verrica Pharmaceuticals (VRCA)
(Delayed Data from NSDQ)
$5.64 USD
+0.01 (0.18%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $5.60 -0.04 (-0.71%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Fundamental Charts
About Market Cap
As of the previous market close, Verrica Pharmaceuticals Inc. has a market cap of $52.07M, which represents its share price of $5.63 multiplied by its outstanding shares number of 9.25M. As a small-cap company, VRCA's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
VRCA 5.64 +0.01(0.18%)
Will VRCA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for VRCA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VRCA
Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimates
Assertio (ASRT) Reports Q1 Loss, Misses Revenue Estimates
VRCA: What are Zacks experts saying now?
Zacks Private Portfolio Services
4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates
Amneal Pharmaceuticals (AMRX) Q1 Earnings Beat Estimates
Here's Why Verrica Pharmaceuticals (VRCA) Is a Great 'Buy the Bottom' Stock Now
Other News for VRCA
VRCA Trading Halted: Anticipation Builds for Pending Announcement | VRCA Stock News
Verrica Parmaceuticals trading halted, news pending
12 Health Care Stocks Moving In Thursday's After-Market Session
Verrica Pharmaceuticals (VRCA) Reports Robust Growth in YCANTH Sales
Verrica Pharmaceuticals reports 13,434 YCANTH dispensed applicator units in Q2